Lauralie Korey
Medical · Atlanta, GANPI 1295885911
Payments from drug & device makers
Across 448 payments — averaging $17.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- Lilly USA, LLC$726
- Boehringer Ingelheim$715
- Insulet Corporation$446
- Sanofi-aventis U.S. LLC$418
- Xeris Pharmaceuticals, Inc.$365
- plus $4K from 43 others
What the payments were for
- Food & beverage$7,744100%
- Education$200%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$7,764 in reported general payments places this provider in the 90th percentile of 950 medical providers in Georgia.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 167 | $209,568 |
| MounjaroTirzepatide | 81 | $115,027 |
| JardianceEmpagliflozin | 95 | $86,411 |
| FarxigaDapagliflozin Propanediol | 74 | $73,317 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 46 | $57,338 |
| Humulin R U-500Insulin Regular, Human | 20 | $36,278 |
| Tresiba Flextouch U-200Insulin Degludec | 20 | $33,028 |
| Bydureon BciseExenatide Microspheres | 17 | $25,687 |
| TrulicityDulaglutide | 17 | $25,657 |
| Tresiba Flextouch U-100Insulin Degludec | 29 | $19,463 |
| JanuviaSitagliptin Phosphate | 17 | $14,184 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 16 | $13,935 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 12 | $11,951 |
| SynthroidLevothyroxine Sodium | 125 | $10,253 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 16 | $9,335 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Novolog | $1,165 | $217,186180 claims |
| Lilly USA, LLCMounjaro, Trulicity, Insulin Lispro | $726 | $145,531138 claims |
| Boehringer IngelheimJardiance | $715 | $86,41195 claims |
| AstraZenecaFarxiga | $147 | $73,31774 claims |
| MerckJanuvia | $105 | $14,18417 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $418 | $13,93516 claims |
| AbbVieSynthroid | $44 | $10,253125 claims |
| Amneal Pharmaceuticals LLCUnithroid, Levothyroxine Sodium | $214 | $2,816154 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 950 medical providers in Georgia.
Other medical in Atlanta
- Kimberly OrleckAtlanta$727K
- Danna Dennis-CalderAtlanta$87K
- Ferrina ShethAtlanta$49K
- Adriana RuizAtlanta$39K
- Punam PunjaAtlanta$31K
- Adrienne AndersonAtlanta$25K
- Jeremiah RobinsonAtlanta$23K
- Steven SchmittAtlanta$15K
- Taylor WeintraubAtlanta$15K
- Margaret SellersAtlanta$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.